Breaking News Instant updates and real-time market news.

2018-10-15 10:20:32

PBYI

Puma Biotechnology

$42.19

-0.5 (-1.17%)

, RHHBY

Roche

$0.00

(0.00%)

10:20

10/15/18

10/15

10:20

10/15/18

10:20

Roche breast cancer data could pressure Puma shares, says RBC Capital

RBC Capital analyst Kennen MacKay thinks the data presented this morning by Roche's (RHHBY) Genentech could pressure shares of Puma Biotechnology (PBYI) today. Genentech announced the Phase III Katherine study met its primary endpoint, showing Kadcyla as a single agent reduced the risk of disease recurrence or death compared to Herceptin as an adjuvant treatment in people with HER2-positive early breast cancer who have residual disease present following neoadjuvant treatment. Kadcyla's ultimate entry into the HER2-positive adjuvant setting could complicate the positioning of Puma's Nerlynx, MacKay tells investors in a research note. He keeps a Sector Perform rating on shares of Puma, which are down 4%, or $1.55, to $41.14 in morning trading.

Goldman Sachs analyst Paul Choi started Puma Biotechnology with a Sell rating and $42 price target. The analyst sees see 11% downside in the shares versus 20% upside on average for his coverage universe. While the company's Nerlynx launch in the extended adjuvant setting in HER2+ breast cancer has gone well to date, channel checks and analysis suggest that consensus estimates are overly optimistic with respect to patient adds in this setting, Choi tells investors in a research note. The analyst initiated coverage of the smid-cap biotech sector with a Neutral coverage view. He views sector fundamentals as healthy but says high valuations temper his enthusiasm.

Citi analyst Yigal Nochomovitz says his 100-physician survey of U.S. oncologists supports his "long-standing bull thesis" that Puma Biotechnology's Nerlynx is positioned to be a billion-dollar drug. Continued fundamental upside to the launch should limit investor concerns around a "stalled" launch that has been pressuring the stock, Nochomovitz tells investors in a research note. The survey indicates that one-in-four adjuvant Herceptin patients are expected to receive Nerlynx. This provides "substantive validation" that 20%-25% of Herceptin completers are high-risk and thus likely Nerlynx patients, Nochomovitz contends. The analyst lowered his price target for Puma shares to $151 from $164 and keeps a Buy rating on the name.

10/01/18

CANT

10/01/18INITIATIONTarget $75CANTOverweight

Puma Biotechnology initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald analyst Alethia Young started Puma Biotechnology with an Overweight rating and $75 price target.

Piper Jaffray analyst Christopher Raymond believes investor sentiment on Biogen (BIIB) overlooks the H2H tolerability data for BIIB098 versus Tecfidera coming in the first half of 2018 Though BIIB098 is largely discounted as an intellectual property play "or worse," the readout, if positive, may be an important catalyst ahead of FDA approval in Q4 of 2019, Raymond tells investors in a research note. He suspects that if BIIB098 shows meaningful tolerability improvement over Tecfidera, "docs will likely take notice." Further, Raymond's new neurologist survey indicates that while the launch trends of Roche's (RHHBY) multiple sclerosis drugOcrevus "appear to be improving," other share trends, including those for Tecfidera and Tysabri, "remain stable." The analyst keeps an Overweight rating on Biogen with a $400 price target.

The risdiplam spinal muscular atrophy data released this morning by PTC Therapeutic (PTCT) and Roche (RHHBY) stack up fairly well to Biogen's (BIIB) Spinraza clinical data, Piper Jaffray analyst Christopher Raymond tells investors in a research note. Even taking into account all of the usual caveats regarding cross-trial comparisons, risdiplam is shaping up well compared to Spinraza, the analyst contends. He sees the new data as adding uncertainty to the Spinraza trajectory. Nonetheless, Raymond keeps an Overweight rating on shares of Biogen. The analyst made no changes to his Biogen model, but he admits risdiplam, if the data holds up, may impact Spinraza's ultimate market potential. Biogen in midday trading is up 2% to $351.41.

10/03/18

BARD

10/03/18NO CHANGETarget $348BARDNeutral

Risdiplam data incrementally negative for Biogen, says Baird

Biogen analyst Brian Skorney views this morning's risdiplam data for use in treating spinal muscular atrophy patients as incrementally negative for Biogen (BIIB). The data from PTC Therapeutics (PTCT) and PTC Therapeutics (RHHBY) are compelling so far, and suggest that risdiplam could impact the market share of Biogen's Spinraza, if it comes to market, Skorney tells investors in a research note. He highlights risdiplam's convenience as an oral small molecule and says the Phase II data "continues to impress." The analyst keeps a Neutral rating on Biogen with a $348 price target. The stock in afternoon trading is up $6.90, or 2%, to $352.31.

10/08/18

SBSH

10/08/18NO CHANGETarget $470SBSHBuy

Biogen price target lowered to $470 from $483 at Citi

Citi analyst Robyn Karnauskas lowered her price target for Biogen (BIIB) to $470 after reducing her assumptions for Rituxan/Gazyva co-promotion profits to reflect greater erosion from biosimilar versions of Rituxan that are expected to launch late 2018/early 2019. The analyst points out that consensus estimates are not modeling significant co-promotion profit erosion from Rituxan biosimilars. However, the Roche (RHHBY) consensus for Rituxan has steep declines in Rituxan sales, Karnauskas tells investors in a research note. The analyst now models a 45% total decline in Rituxan/Gazyva U.S. sales over 2018-2023. She keeps a Buy rating on Biogen.